146.64 0.00 (0.00%)
After hours: 4:43PM EDT
|Bid||137.01 x 1800|
|Ask||149.15 x 800|
|Day's Range||146.13 - 156.93|
|52 Week Range||87.49 - 199.70|
|Beta (3Y Monthly)||2.78|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 30, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||175.89|
bluebird bio, Inc. (BLUE) today announced the official opening of its first wholly owned manufacturing facility in Durham, N.C., that will produce lentiviral vector for the company’s investigational gene and cell therapies, including: bb2121 and bb21217 for the treatment of multiple myeloma and potentially LentiGlobin™ for the treatment of transfusion-dependent β-thalassemia (TDT) and sickle cell disease. Gov. Roy Cooper, Secretary of Commerce Tony Copeland and local patient advocates will join chief bluebird Nick Leschly in a ribbon cutting ceremony at the 125,000-square-foot facility.
bluebird bio Inc NASDAQ/NGS:BLUEView full report here! Summary * Bearish sentiment is high Bearish sentimentShort interest | NegativeShort interest is high for BLUE with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting BLUE. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BLUE had net inflows of $1.45 billion over the last one-month. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
To access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully.
bluebird bio, Inc.'s (NASDAQ:BLUE) most recent earnings update in December 2018 signalled that losses became smaller relative to the prior year's level - great news for investors Below is aRead More...
Bluebird (BLUE) delivered earnings and revenue surprises of 3.89% and 96.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.72. The results beat Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment ...
- Strong 2018 marked by the company’s first European Marketing Authorization Application for LentiGlobin in transfusion-dependent β-thalassemia –
NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.
Mr. Baird joins bluebird from Amicus Therapeutics, Inc., where he was the CFO for the past seven years and brings a demonstrated track record of successfully leading companies in all phases of discovery, development and commercialization. Jeff Walsh, who has held various roles over the last eight years at bluebird bio — including chief operating officer and, most recently, chief financial and strategy officer — will assume the new dedicated role of chief strategy officer to drive corporate development and the company’s overall growth strategy.
Ahead of the opening this week, the German biotech firm signed two major partnerships with Boston-based Orchard Therapeutics and San Francisco-based Denali Therapeutics, and is also in the process of closing another partnership with a U.S. biotech company focused on hemophilia treatments.
NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged ...
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples Read More...
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio